STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer

Treatment of advanced HER2-positive breast cancer: 2018 and beyond

(2018) Noam Pondé et al.   CANCER TREATMENT REVIEWS

STAT3 and apoptosis challenges in cancer

(2018) Nazanin Fathi et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma

(2018) Siobhan Conroy et al.   Oncotarget

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary

(2018) Sharon H. Giordano et al.   Journal of Oncology Practice

Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4

(2017) Shidong Lv et al.   ONCOGENE

Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer

(2016) Hanlin Zeng et al.   CANCER CELL

TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer

(2016) María F. Mercogliano et al.   CLINICAL CANCER RESEARCH

Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder

(2016) Wei-Jan Wang et al.   CLINICAL CANCER RESEARCH

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

(2016) María Teresa Martínez et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

STAT3-dependent TXNDC17 expression mediates Taxol resistance through inducing autophagy in human colorectal cancer cells

(2016) Zhongde Zhang et al.   GENE

Role of interleukin-6 in cancer progression and therapeutic resistance

(2016) Neeraj Kumari et al.   TUMOR BIOLOGY

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

(2015) Amir Sonnenblick et al.   BMC Medicine

Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer

(2015) Adela Madrid-Paredes et al.   BREAST CANCER RESEARCH AND TREATMENT

Leukemia inhibitory factor (LIF)

(2015) Nicos A. Nicola et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Suppression of cancer relapse and metastasis by inhibiting cancer stemness

(2015) Youzhi Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma

(2015) Fabiana Salm et al.   PLoS One

Trastuzumab emtansine: mechanisms of action and drug resistance

(2014) Mark Barok et al.   BREAST CANCER RESEARCH

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits

(2013) SEYUNG S. CHUNG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates

(2013) Michael Ritchie et al.   mAbs

Tumour heterogeneity and cancer cell plasticity

(2013) Corbin E. Meacham et al.   NATURE

(5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition

(2012) Lei Wang et al.   CANCER LETTERS

Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population

(2012) Hasan Korkaya et al.   MOLECULAR CELL

Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression

(2011) Stefania Nobili et al.   MEDICINAL RESEARCH REVIEWS

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

(2010) Teemu T. Junttila et al.   BREAST CANCER RESEARCH AND TREATMENT

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Tn Glycosylation of the MUC6 Protein Modulates Its Immunogenicity and Promotes the Induction of Th17-biased T Cell Responses

(2010) Teresa Freire et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

(2008) Q. Ryan et al.   ONCOLOGIST

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH